org 31710 has been researched along with ulipristal in 2 studies
| Studies (org 31710) | Trials (org 31710) | Recent Studies (post-2010) (org 31710) | Studies (ulipristal) | Trials (ulipristal) | Recent Studies (post-2010) (ulipristal) |
|---|---|---|---|---|---|
| 38 | 3 | 6 | 94 | 14 | 34 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goyeneche, AA; Seidel, EE; Telleria, CM | 1 |
| Gamarra-Luques, CD; Goyeneche, AA; Hapon, MB; Telleria, CM | 1 |
2 other study(ies) available for org 31710 and ulipristal
| Article | Year |
|---|---|
Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytostatic Agents; DNA Fragmentation; Estrenes; Female; Furans; Hormone Antagonists; Humans; Mifepristone; Norpregnadienes; Ovarian Neoplasms | 2012 |
Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estrenes; Female; Furans; Hormone Antagonists; Humans; Inhibitory Concentration 50; Mifepristone; Norpregnadienes; Paclitaxel | 2014 |